Amplia Therapeutics Ltd - FDA Awards Amplia Orphan Drug Designation for Pancreatic Cancer
Amplia Therapeutics Ltd (ASX:ATX)

FDA Awards Amplia Orphan Drug Designation for Pancreatic Cancer

Published Mar 25, 2020

What happened?


What's happened?

Amplia Therapeutics Limited (ASX: ATX, “Amplia”) today announced that the United States Food and Drug Administration (FDA) has awarded Amplia’s Focal Adhesion Kinase inhibitor (FAKi) AMP945 Orphan-Drug Designation for the treatment of pancreatic cancer.

What are the key highlights?

  1. The designation means that Amplia will qualify for waived FDA fees, clinical trial protocol assistance and other incentives.
  2. If the FDA ultimately approves AMP945 for the treatment of pancreatic cancer, Amplia would qualify for seven years’ market exclusivity in FDA-administered markets.
  3. Amplia is aiming to start a Phase 1 clinical trial of AMP945 in healthy volunteers later this year to confirm that, like other FAKi, it is well tolerated.

Download Announcement

View this announcement as well as our full profile on the company.

Comments

Share your thoughts about this announcement...

Similar articles
Amplia Receives Human Research Ethics Committee Clearance to Conduct Phase 1 Clinical Trial
What's happened? Amplia Therapeutics Limited (ASX: ATX, "Amplia") has received clearance from the Alfred Hospi...
3 years ago
Amplia Appoints Dr Mark Devlin as Chief Scientific Officer
What's happened? Amplia Therapeutics Limited (ASX: ATX, "Amplia") has announced that it has appointed Dr. Mark...
3 years ago
Amplia Appoints Nucleus Network to Conduct Phase 1 Clinical Trial
What's happened? Amplia Therapeutics Limited (ASX: ATX) has appointed the Nucleus Network in Melbourne to conduct its up...
3 years ago
Around the web
Amplia Therapeutics updates on next stage of ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) is progressing thee Phase 2a stage of the ACCENT trial involvi...
via biotechdispatch.com.au
Amplia Therapeutics takes step up in pancreatic cancer treatment
Amplia Therapeutics (ASX:ATX) has progressed its ACCENT trial to evaluate narmafotinib, a drug that...
via themarketonline.com.au
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
via stockhead.com.au
Powered by  
  • Company
    Amplia Therapeutics Ltd
  • Website
  • Sector
    Biotechnology
  • Industry
    Biotechnology
  • Code
    ASX:ATX
  • Socials
View Amplia Therapeutics Ltd's Profile

How do I invest?

Considering investing in Amplia Therapeutics Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:ATX

    On your online investment platform search for the stock ticker code ASX:ATX to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up